Investors & Media Press Releases Investor Relations Overview Corporate Governance Press Releases & Statements Events & Presentations SEC Filings Annuals and Proxies Investor FAQs Financials & Filings Stock Information Analyst Coverage Email Alerts Subscription Notice of Pendency of Settlement of Action Press Releases Items Per Page 102550 Year None20242023202220212020201920182017 Date Title View Toggle Summary January 31, 2024 Dalzanemdor (SAGE-718) Awarded Innovation Passport Designation for Cognitive Impairment Associated with Huntington’s Disease and Entry into the Innovative Licensing and Access Pathway by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) Dalzanemdor (SAGE-718) Awarded Innovation Passport Designation for Cognitive Impairment Associated with Huntington’s Disease and Entry into the Innovative Licensing and Access Pathway by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) Toggle Summary January 31, 2024 Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024 Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024 Toggle Summary January 8, 2024 Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference Toggle Summary January 8, 2024 Sage Therapeutics Announces Changes to Board of Directors Sage Therapeutics Announces Changes to Board of Directors Toggle Summary January 2, 2024 Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 Pagination First page First Previous page Previous Page 1 Page 2 Current page 3 Displaying 21 - 25 of 25
Press Releases Items Per Page 102550 Year None20242023202220212020201920182017 Date Title View Toggle Summary January 31, 2024 Dalzanemdor (SAGE-718) Awarded Innovation Passport Designation for Cognitive Impairment Associated with Huntington’s Disease and Entry into the Innovative Licensing and Access Pathway by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) Dalzanemdor (SAGE-718) Awarded Innovation Passport Designation for Cognitive Impairment Associated with Huntington’s Disease and Entry into the Innovative Licensing and Access Pathway by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) Toggle Summary January 31, 2024 Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024 Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024 Toggle Summary January 8, 2024 Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference Toggle Summary January 8, 2024 Sage Therapeutics Announces Changes to Board of Directors Sage Therapeutics Announces Changes to Board of Directors Toggle Summary January 2, 2024 Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 Pagination First page First Previous page Previous Page 1 Page 2 Current page 3 Displaying 21 - 25 of 25
